The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programsBOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease research, today announced the launch of its NHP Fast-Tox Program, an early toxicology screening solution designed to help biotech companies evaluate...